Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Yabao, Lawson deal advances to preclinical stage
September 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

BEIJING—Yabao Pharmaceutical Co. Inc. signed an exclusive license with Lawson Health Research Institute in July 2014 for the discovery, development and commercialization of products based on annexin A5 for the treatment of sepsis, and recently announced the successful completion of discovery validation work and that the program has progressed into preclinical development.
 
“Yabao is pleased to collaborate with Lawson, a leading Canadian research institute focused on improving the lives of patients through medical discovery. Yabao is also very pleased that the program has been moving very smoothly, showing great potential as a novel drug candidate for a huge unmet medical need,” said Dr. Peng Wang, Yabao’s president of research and development. “This opportunity for Yabao to further develop leading research into innovative products is further evidence of Yabao’s growing commitment to partner the best science to treat serious diseases in China.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.